ERBB2 and breast carcinoma: Phase 1 dose escalation to 32 mg candesartan, which had been tolerated in HER2+ breast cancer patients, was not tolerated in advanced PDAC patients, potentially reflecting the higher burden of disease-related comorbidities in this cohort.